Menu

ISTOCK, CIPHOTOS

Bioethics Council: Gene-Editing Human Embryos Conditionally OK

The UK-based organization encourages public debate about the issue but does not recommend immediate policy change.

Jul 17, 2018
Shawna Williams

The Nuffield Council on Bioethics, an influential, independent body in the U.K. that provides recommendations on medical and biological questions, released a report today (July 17) suggesting that gene-editing of human embryos should be permissible in some circumstances. UK law currently prohibits making alterations to people that could be passed down to future generations, and the report stops short of recommending an immediate change to that policy, but instead encourages public debate around what regulations should be in place.

“It is our view that genome editing is not morally unacceptable in itself,” Karen Yeung, chair of the working group behind the report and a professor of law, ethics, and informatics at the University of Birmingham, tells The Guardian. “There is no reason to rule it out in principle.”

See “Review: The End of Sex

The working group recommends that changing embryos’ genes should only be permitted when the intervention would benefit the future child, and when doing so would not run the risk of exacerbating social inequality by conferring genetic advantages on those whose parents could afford it. 

David King of the UK-based advocacy group Human Genetics Alert tells Reuters in an email that the committee had effectively approved of creating “designer babies. . . . We must have an international ban on creating genetically engineered babies.” 

Marcy Darnovsky of the Center for Genetics and Society also took a dim view of the report, telling The Guardian, “In practical terms, they have thrown down a red carpet for unrestricted use of inheritable genetic engineering, and a gilded age in which some are treated as genetic ‘haves’ and the rest of us as ‘have-nots.’” 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.